Table 1.
Demographic and Baseline Clinical Characteristics
| Rasagiline | Placebo | |
|---|---|---|
| N | 28 | 29 |
| Age (y; ±SD) | 46.3 (12.2) | 45.9 (11.1) |
| Gender (N; % male) | 24; 85.7 | 22; 75.9 |
| Race (N) | ||
| White | 18; 64.3% | 17; 68.6% |
| Black | 8; 28.7% | 12; 41.4% |
| Other | 2; 7.1% | 0 |
| Education (y; ±SD) | 12.9 (2.5) | 12.1 (2.4) |
| Marital status | ||
| Never married | 23; 82.1% | 27; 93.1% |
| Presently married | 2; 7.1% | 0 |
| Divorced | 3; 10.7% | 2; 6.9% |
| Diagnosis (N; % schizophrenia) | 20 (71.4) | 25 (86.2) |
| Age of onset (y; ±SD) | 19.7 (7.9)a | 20.5 (5.1)b |
| SANS total score (±SD) | 32.5 (8.5) | 33.5 (7.8) |
| BPRS total score (±SD) | 33.7 (6.9) | 33.3 (6.4) |
| BPRS positive symptom item score (±SD) | 8.7 (3.2) | 9.1 (4.0) |
| CDS total score (±SD) | 2.3 (2.1) | 2.0 (2.4) |
| CGI severity of illness (±SD) | 4.0 (0.4) | 4.3 (0.5) |
Note: BPRS, Brief Psychiatric Rating Scale; CDS, Calgary Depression Scale; CGI, Clinical Global Impression; SANS, Scale for the Assessment of Negative Symptoms.
a N = 27.
b N = 28.